Matinas BioPharma
NYSEAMERICAN:MTNBMatinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nanocrystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, nucleic acids, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is LYPDISO, a prescription-only omega-3 fatty acid-based composition intended for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that is in Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Allergy and Infectious Diseases for the development of Gilead's antiviral remdesivir; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. Matinas BioPharma Holdings, Inc. was incorporated in 2013 and is based in Bedminster, New Jersey.
Pfenex
NYSEAMERICAN:PFNXPfenex Inc., a clinical-stage development and licensing biotechnology company, focuses on developing protein therapies for unmet patient needs. Its lead product candidates include PF708, a therapeutic equivalent drug candidate to Forteo (teriparatide) for the treatment of osteoporosis; and novel anthrax vaccine candidates, such as Px563L and RPA563 that have completed Phase Ia clinical study. The company also develops PF582, a biosimilar candidate to Lucentis; PF529, a biosimilar to Neulasta; and hematology/oncology products, including PF743, a recombinant crisantaspase, as well as PF745, a recombinant crisantaspase with half-life extension technology. In addition, it has license and supply agreements for CRM197, a non-toxic mutant of diphtheria toxin. Pfenex Inc. is headquartered in San Diego, California.
ProMetic Life Sciences
TSE:PLIPrometic Life Sciences Inc. operates as a biopharmaceutical company with two drug discovery platforms that focuses on unmet medical needs in the field of fibrosis and orphan diseases. Its product pipeline includes PBI-4050, an orally active lead drug candidate for fibrosis; plasminogen, a biopharmaceutical for the treatment of congenital plasminogen deficiency; and intravenous immunoglobulin, a preparation of antibodies purified from plasma donations from healthy individuals. The company was founded in 1992 and is based in Laval, Canada.
Target Hospitality
NASDAQ:THTarget Hospitality Corp. operates as a specialty rental and hospitality services company in North America. The company operates through two segments, Hospitality & Facilities Services - South and Government. It owns a network of specialty rental accommodation units. In addition, the company provides catering and food, maintenance, housekeeping, grounds-keeping, security, health and recreation facilities, workforce community management, concierge, and laundry services. It serves the U.S. government contractors and investment grade natural resource development companies. Target Hospitality Corp. was founded in 1978 and is headquartered in The Woodlands, Texas.